Shandong Cancer Hospital & Institute

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric neoplasm, gastroesophageal junction adenocarcinoma, neoplasm, stomach disorder	Active, not recruiting	Phase 3	2026-05-27	NCT04704934
Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors; Unresectable	Recruiting	Phase 1	2025-01-22	NCT06418061
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder	Recruiting	Phase 2	2024-02-28	NCT06155396

Clinical trials